{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 56,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 60,
  "notes": "The table displays counts and percentages of patients experiencing specific adverse events, categorized by severity (All vs Grade >= 3).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/35",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.76,
        "x": 0.12,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Treatment-related Adverse Events occurring in ≥ 20% of patients in QD and BID cohorts",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "333c1d92-e878-4ebc-aaf9-638a3ad8cd5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.02,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "* Includes thrombocytopenia and platelet count decrease\nSource: ENA 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb1f9d9a-1e8a-4b7d-91d1-140bc95ade90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.88,
        "x": 0.06,
        "y": 0.29
      },
      "kind": "table",
      "text": "System Organ Class/Preferred Term, QD (20-80 mg) N=15, QD MTD (40 mg) N=3, BID (20 and 40 mg) N=13, BID MTD (40 mg) N=9, QD + BID N=28, At least one TRAE, Thrombocytopenia*, AST increased, ALT increased, Diarrhea, Oedema peripheral",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c58d1750-ad75-4378-8800-e6c1569ebd25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "ERAS-601 QD and BID regimens were well tolerated with acceptable safety profile",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cf969d9-7d2a-4cbd-978c-fbc820583a21",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "ba61e41c-fca4-41cc-9b56-5c539acb8d04",
      "evidence": "System Organ Class/Preferred Term table",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}